NCT06982547View on ClinicalTrials.gov

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2040

Conditions
Rheumatoid Arthritis (RA)
Interventions
BIOLOGICAL

UTAA91 injection

After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.

Trial Locations (1)

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY